Evidence map›Paper›PMID 36536830›Full record

ReviewDiscover materials2022

Microfluidic SERS devices: brightening the future of bioanalysis.

Maria João Oliveira, Ana Dalot, Elvira Fortunato, Rodrigo Martins, Hugh J Byrne, Ricardo Franco, Hugo Águas

Abstract readReview
In one paragraph

Review in Discover materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Applications and prospects of biomaterials in diabetes management.Frontiers in bioengineering and biotechnology · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria João OliveiraCENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal.
Ana DalotCENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal.
Elvira FortunatoCENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal.
Rodrigo MartinsCENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal.
Hugh J ByrneFOCAS Research Institute, Technological University Dublin, Camden Row, Dublin 8, Dublin, Ireland.
Ricardo FrancoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
Hugo ÁguasCENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new avenue has opened up for applications of surface-enhanced Raman spectroscopy (SERS) in the biomedical field, mainly due to the striking advantages offered by SERS tags. SERS tags provide indirect identification of analytes with rich and highly specific spectral fingerprint information, high sensitivity, and outstanding multiplexing potential, making them very useful in in vitro and in vivo assays. The recent and innovative advances in nanomaterial science, novel Raman reporters, and emerging bioconjugation protocols have helped develop ultra-bright SERS tags as powerful tools for multiplex SERS-based detection and diagnosis applications. Nevertheless, to translate SERS platforms to real-world problems, some challenges, especially for clinical applications, must be addressed. This review presents the current understanding of the factors influencing the quality of SERS tags and the strategies commonly employed to improve not only spectral quality but the specificity and reproducibility of the interaction of the analyte with the target ligand. It further explores some of the most common approaches which have emerged for coupling SERS with microfluidic technologies, for biomedical applications. The importance of understanding microfluidic production and characterisation to yield excellent device quality while ensuring high throughput production are emphasised and explored, after which, the challenges and approaches developed to fulfil the potential that SERS-based microfluidics have to offer are described.

Identifiers

PMID36536830
PMCPMC9751519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.